Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 28 12% Improvement Relative Risk Mortality, day 14 1% WHO scale, day 28 8% WHO scale, day 14 6% primary Ortigoza et al. NCT04364737 CONTAIN COVID-19 Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 941 patients in the USA (April 2020 - March 2021) Lower mortality with convalescent plasma (not stat. sig., p=0.45) Ortigoza et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6850 Favors conv. plasma Favors control
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6850, CONTAIN COVID-19, NCT04364737 (history)
Ortigoza et al., Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients, JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6850, CONTAIN COVID-19, NCT04364737
Dec 2021   Source   PDF  
  All Studies   Meta
RCT 941 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment.
risk of death, 11.8% lower, RR 0.88, p = 0.45, treatment 59 of 462 (12.8%), control 71 of 462 (15.4%), NNT 39, odds ratio converted to relative risk, day 28.
risk of death, 1.3% lower, RR 0.99, p = 0.95, treatment 35 of 463 (7.6%), control 39 of 463 (8.4%), NNT 116, odds ratio converted to relative risk, day 14.
WHO scale, 7.6% lower, OR 0.92, p = 0.50, treatment 468, control 473, day 28, RR approximated with OR.
WHO scale, 6.4% lower, OR 0.94, p = 0.58, treatment 468, control 473, day 14, primary outcome, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ortigoza et al., 13 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, median age 63.0, 268 authors, study period 17 April, 2020 - 15 March, 2021, average treatment delay 7.0 days, trial NCT04364737 (history) (CONTAIN COVID-19).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: Research JAMA Internal Medicine | Original Investigation Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients A Randomized Clinical Trial Mila B. Ortigoza, MD, PhD; Hyunah Yoon, MD; Keith S. Goldfeld, DrPH; Andrea B. Troxel, ScD; Johanna P. Daily, MD, MS; Yinxiang Wu, MA; Yi Li, MS; Danni Wu, MS; Gia F. Cobb, MA; Gillian Baptiste, MD; Mary O’Keeffe, MD; Marilou O. Corpuz, MD; Luis Ostrosky-Zeichner, MD; Amee Amin, MD; Ioannis M. Zacharioudakis, MD; Dushyantha T. Jayaweera, MD; Yanyun Wu, MD; Julie V. Philley, MD; Megan S. Devine, MD; Mahalia S. Desruisseaux, MD; Alessandro D. Santin, MD; Shweta Anjan, MD, MBBS; Reeba Mathew, MD; Bela Patel, MD; Masayuki Nigo, MD; Rabi Upadhyay, MD; Tania Kupferman, MD; Andrew N. Dentino, MD; Rahul Nanchal, MD, MS; Christian A. Merlo, MD, MPH; David N. Hager, MD, PhD; Kartik Chandran, PhD; Jonathan R. Lai, PhD; Johanna Rivera, PhD; Chowdhury R. Bikash, PhD; Gorka Lasso, PhD; Timothy P. Hilbert, MD; Monika Paroder, MD, PhD; Andrea A. Asencio, BA; Mengling Liu, PhD; Eva Petkova, PhD; Alexander Bragat, MBA; Reza Shaker, MD; David D. McPherson, MD; Ralph L. Sacco, MD, MS; Marla J. Keller, MD; Corita R. Grudzen, MD; Judith S. Hochman, MD; Liise-anne Pirofski, MD; and the CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group Visual Abstract IMPORTANCE There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in Supplemental content patients hospitalized with COVID-19. OBJECTIVE To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. DESIGN, SETTING, AND PARTICIPANTS CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19, was conducted at 21 US hospitals from April 17, 2020, to March 15, 2021. The trial enrolled 941 participants who were hospitalized for 3 or less days or presented 7 or less days after symptom onset and required noninvasive oxygen supplementation. INTERVENTIONS A unit of approximately 250 mL of CCP or equivalent volume of placebo (normal saline). MAIN OUTCOMES AND MEASURES The primary outcome was participant scores on the 11-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement on day 14 after randomization; the secondary outcome was WHO scores determined on day 28. Subgroups were analyzed with respect to age, baseline WHO score, concomitant medications, symptom duration, CCP SARS-CoV-2 titer, baseline SARS-CoV-2 serostatus, and enrollment quarter. Outcomes were analyzed using a bayesian proportional cumulative odds model. Efficacy of CCP was defined as a cumulative adjusted odds ratio (cOR) less than 1 and a clinically meaningful effect as cOR less than 0.8. RESULTS Of 941 participants randomized (473 to placebo and 468 to CCP), 556 were men (59.1%); median age was 63 years (IQR, 52-73); 373 (39.6%) were Hispanic and 132 (14.0%) were non-Hispanic Black. The cOR for the primary outcome adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval [CrI], 0.75-1.18) with posterior probability (P[cOR<1] = 72%); the cOR for the secondary adjusted outcome was 0.92 (95% CrI, 0.74-1.16; P[cOR<1] = 76%). Exploratory subgroup analyses suggested heterogeneity of treatment effect: at day 28, cORs were 0.72 (95% CrI, 0.46-1.13; P[cOR<1] = 93%) for participants enrolled in April-June 2020 and 0.65 (95% CrI, 0.41 to 1.02; P[cOR<1] = 97%)..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop